利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

25 条记录 (耗时 0.027 秒)

    Combination comprising N--4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent.
    8.
    发明申请
    Combination comprising N--4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent. 审中-公开
    包含N-4-（3-吡啶基）-2嘧啶胺和化学治疗剂的组合。

    公开(公告)号：US20120283206A1

    公开(公告)日：2012-11-08

    申请号：US13551079

    申请日：2012-07-17

    申请人： Christian Bruns ,  Elisabeth Buchdunger ,  Terence O'Reilly ,  Sandra Leta Siberman ,  Markus Wartmann ,  Gisbert Weckbecker

    发明人： Christian Bruns ,  Elisabeth Buchdunger ,  Terence O'Reilly ,  Sandra Leta Siberman ,  Markus Wartmann ,  Gisbert Weckbecker

    IPC分类号： A61K31/506 ,  A61K31/675 ,  A61P37/06 ,  A61K31/704 ,  A61P35/00

    CPC分类号： A61K45/06 ,  A61K31/506

    摘要： A method of treating a warm-blooded animal, especially a human, having a proliferative disease or acute or chronic transplant rejection comprising administering to the animal a combination which comprises (a) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and (b) a chemotherapeutic agent selected from antineoplastic agents, especially as defined herein, and agents effective in treating acute or chronic transplant rejection; a combination comprising (a) and (b) as defined above and optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the delay of progression or treatment of a proliferative disease, especially a solid tumor disease.

    摘要翻译： 一种治疗具有增殖性疾病或急性或慢性移植排斥反应的温血动物，特别是人的方法，包括向动物施用包含（a）N- {5- [4-（4-甲基 - 哌嗪子基） - 甲基） - 苯甲酰氨基] -2-甲基苯基} -4-（3-吡啶基）-2-嘧啶胺和（b）选自抗肿瘤剂，特别是本文所定义的化学治疗剂和有效治疗急性或慢性的药物 移植排斥反应 包含如上定义的（a）和（b）和任选的至少一种用于同时，分开或顺序使用的药学上可接受的载体的组合，特别是用于延缓进展或治疗增殖性疾病，特别是实体肿瘤疾病。

    COMBINATIONS COMPRISING EPOTHILONES AND PHARMACEUTICAL USES THEREOF
    10.
    发明申请
    COMBINATIONS COMPRISING EPOTHILONES AND PHARMACEUTICAL USES THEREOF 审中-公开
    包含EPOTHILONES及其药物用途的组合

    公开(公告)号：US20110033458A1

    公开(公告)日：2011-02-10

    申请号：US12908533

    申请日：2010-10-20

    申请人： John Arthur Hohneker ,  Julie Ann Miller ,  John David Rothermel ,  Markus Wartmann

    发明人： John Arthur Hohneker ,  Julie Ann Miller ,  John David Rothermel ,  Markus Wartmann

    IPC分类号： A61K39/395 ,  A61K31/427 ,  A61P35/00

    CPC分类号： C07K16/3015 ,  A61K31/426 ,  A61K31/427 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  C07D417/06 ,  A61K2300/00

    摘要： The invention relates to a pharmaceutical combination which comprises (a) a HER-1 or a HER-2 antibody or (b) at least one antineoplastic agent selected from the group consisting of aromatase inhibitors, antiestrogens, topoisomerase I inhibitors, topoisomerase II inhibitors, microtubule active agents, protein kinase C inhibitors, anti-angiogenic compounds, gonadorelin agonists, anti-androgens, histone deacetylase inhibitors and S-adenosylmethionine decarboxylase inhibitors; and (c) an epothilone derivative of formula I and optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular, for the treatment of a proliferative disease, especially a solid tumor disease; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of a proliferative disease; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a warm-blooded animal, especially a human.

    摘要翻译： 本发明涉及药物组合，其包含（a）HER-1或HER-2抗体或（b）至少一种抗肿瘤剂，其选自芳香酶抑制剂，抗雌激素，拓扑异构酶I抑制剂，拓扑异构酶II抑制剂， 微管活性剂，蛋白激酶C抑制剂，抗血管生成化合物，促性腺激素激动剂，抗雄激素，组蛋白脱乙酰酶抑制剂和S-腺苷甲硫氨酸脱羧酶抑制剂; 和（c）式I的埃坡霉素衍生物和任选的至少一种用于同时，分别或顺序使用的药学上可接受的载体，特别是用于治疗增殖性疾病，特别是实体肿瘤疾病; 包含这种组合的药物组合物; 使用这种组合来制备用于治疗增殖性疾病的药物; 包括作为用于同时，分开或顺序使用的组合制剂的组合的商业包装或产品; 以及治疗温血动物，特别是人的方法。